The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction

Transplantation

Volumn 91, Issue 8, 2011, Pages 853-857

  Fuchinoue, Shohei ^a   Ishii, Yasuo ^a   Sawada, Tokihiko ^b   Murakami, Toru ^a   Iwadoh, Kazuhiro ^a   Sannomiya, Akihito ^a   Koyama, Ichiro ^a   Kubota, Keiichi ^b   Tojimbara, Tamotsu ^c   Nakajima, Ichiro ^a   Teraoka, Satoshi ^c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c International University of Health and Welfare   (Japan)

Author keywords

ABO incompatible; Kidney transplantation; Rituximab

Indexed keywords

CREATININE; RITUXIMAB;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954956691     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820f08e8     Document Type: Article

References (14)

1. Sawada T, Fuchinoue S, Teraoka S. Successful A1 to O, ABOincompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double filtration plasmapheresis. Transplantation 2002; 74: 1207.
2. Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18: 254.
3. Saito K, Nakagawa Y, Suwa M, et al. Pinpoint targeted immunosuppression: Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006; 13: 111.
4. Tanabe K, Ishida H, Shimizu T, et al. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61.
5. Aranda JM Jr, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: A case report. Transplantation 2002; 73: 907.
6. Maloney DG, Grillo-Ló pez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188.
7. De Vita S, Zaja F, Sacco S, De Candia A, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenic role of B cells. Arthritis Rheum 2002; 46: 2029.
8. Kneitz C, Wihelm M, Tony H. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206: 519.
9. Tydén G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145.
10. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
11. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996.
12. Alausa M, Almagro U, Siddiqi N, et al. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005; 19: 137.
13. Tydén G, Genberg H, Tollemar J, et al. A randomized, double-blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
14. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidneytransplant patients. Am J Transplant 2010; 10: 89.